Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

被引:0
作者
Mengu Sarioglu
Cigdem Tuzun
Zeliha Unlu
Canan Tikiz
Fatma Taneli
B. Sami. Uyanik
机构
[1] University of Celal Bayar,Department of Physical Medicine and Rehabilitation, Faculty of Medicine
[2] University of Celal Bayar,Department of Biochemistry, Faculty of Medicine
来源
Rheumatology International | 2006年 / 26卷
关键词
Osteoporosis; Alendronate; Risedronate; Bone turnover markers; Bone mineral density;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the study was to compare the effects of once-weekly alendronate sodium and daily risedronate sodium treatment on bone mineral density (BMD) and bone turnover markers in postmenopausal osteoporotic subjects. For this purpose, 50 patients were included in this study and randomly classified into two groups. Group I (n=25) received risedronate (5 mg/day) and group II (n=25) received alendronate Na (70 mg/week). The study duration was limited to 12 months. The efficacy of the treatment was evaluated by BMD measurements at spine and hip at 6th and 12th months of the treatment, as well as by the measurement of bone turnover markers such as serum osteocalcin (OC), bone-specific alkaline phosphatase (BASP), urine deoxypyridinoline (DPD) and calcium/creatine ratio in 24-h urine at 1st, 3rd, 6th and 12th months. The evaluation of the changes in BMD in all regions revealed a significant increase in BMD in both groups compared to baseline values except for spine (L2–L4) in alendronate group at 6th and 12th month and femoral neck in risedronate group at 6th month. However, the difference in percentage increase in BMD measurements was not statistically significant between the two groups at 6th and 12th months. In both groups, serum OC, BSAP and urine DPD were found to be significantly attenuated at 1st month of the treatment period, and continued to be lowered throughout the 3rd, 6th and 12th months (P<0.05). However, there was no statistically-significant difference between both groups of patients (P>0.05). In conclusion, our results suggest that both treatment protocols provide treatment options of similar efficiencyfor postmenopausal osteoporosis, and have almost-similar effects in enhancing the BMD and in slowing the bone turnover. Risedronate seems to havea more potent effect in the spinal region than that of alendronate, although this potency was not statistically significant.
引用
收藏
页码:195 / 200
页数:5
相关论文
共 182 条
[11]  
LaCroix AZ(1999)Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis JAMA 282 1344-1443
[12]  
Black DM(1995)Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures N Engl J Med 333 1437-1341
[13]  
Yates J(1996)Fracture risk reduction with alendronate in women osteoporosis: the fracture intervention trial: FIT research group Lancet 348 1535-4124
[14]  
Rodan GA(2000)Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial J Clin Endocrinol Metab 85 4118-415
[15]  
McClung M(2002)Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group J Am Geratr Soc 50 409-12
[16]  
Bensen W(2002)Alendronate Once-Weekly Study Group: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis Aging (Milano) 12 1-1996
[17]  
Bologne M(2002)A comparison of the effect of risedronate and ethidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial J Bone Miner Res 17 1988-979
[18]  
Clemmesen B(2002)Postmenopozal osteoporozda ethidronat ve alendronat tedavilerinin karsilastirilmasi Osteoporos Int 13 971-137
[19]  
Ravn P(1999)A comparison of continuous alendronate, cyclical alaendronate and cyclical ethidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial Cukurova Universitesi Tip Fakultesi Dergisi 24 125-966
[20]  
Zegels B(2000)Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study Osteoporos Int 11 956-12